- Home
- CSAI vs FGEN Comparison
CSAI vs FGEN Comparison
Compare CSAI & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSAI
- FGEN
- Stock Information
- Founded
- CSAI N/A
- FGEN 1993
- Country
- CSAI
- FGEN United States
- Employees
- CSAI 18
- FGEN N/A
- Industry
- CSAI
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CSAI
- FGEN Health Care
- Exchange
- CSAI NYSE
- FGEN Nasdaq
- Market Cap
- CSAI 40.8M
- FGEN 33.5M
- IPO Year
- CSAI N/A
- FGEN 2014
- Fundamental
- Price
- CSAI $1.84
- FGEN $5.69
- Analyst Decision
- CSAI
- FGEN Strong Buy
- Analyst Count
- CSAI 0
- FGEN 1
- Target Price
- CSAI N/A
- FGEN $250.00
- AVG Volume (30 Days)
- CSAI N/A
- FGEN 49.2K
- Earning Date
- CSAI N/A
- FGEN 08-05-2025
- Dividend Yield
- CSAI N/A
- FGEN N/A
- EPS Growth
- CSAI N/A
- FGEN N/A
- EPS
- CSAI N/A
- FGEN N/A
- Revenue
- CSAI N/A
- FGEN $6,996,000.00
- Revenue This Year
- CSAI N/A
- FGEN N/A
- Revenue Next Year
- CSAI N/A
- FGEN N/A
- P/E Ratio
- CSAI N/A
- FGEN N/A
- Revenue Growth
- CSAI N/A
- FGEN N/A
- 52 Week Low
- CSAI N/A
- FGEN $4.50
- 52 Week High
- CSAI N/A
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- CSAI N/A
- FGEN 28.80
- Support Level
- CSAI N/A
- FGEN $5.16
- Resistance Level
- CSAI N/A
- FGEN $8.13
- Average True Range (ATR)
- CSAI 0.00
- FGEN 0.58
- MACD
- CSAI 0.00
- FGEN -0.26
- Stochastic Oscillator
- CSAI 0.00
- FGEN 11.13
About CSAI CLOUDASTRUCTURE INC
Cloudastructure Inc is engaged in cloud-based artificial intelligence (AI) video surveillance and Remote Guarding service built on AI and machine learning platforms. Its products/ services include Cloud Video Surveillance, Remote Guarding, Remote Guards, Cloud Video Recorder (CVR), Cameras and Speakers, Mobile Surveillance Trailer, etc.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.